Imunon says Phase 3 ovarian cancer trial enrollment ahead of schedule
Tweet Send to a Friend
Imunon, Inc. (Nasdaq: IMNN) reported that enrollment in its pivotal Phase 3 OVATION 3 trial of IMNN-001 for newly diagnosed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
